First Time Loading...
B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 10.26 HKD 16.86% Market Closed
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Biocytogen Pharmaceuticals Beijing Co Ltd

Wall Street analysts forecast Biocytogen Pharmaceuticals Beijing Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Biocytogen Pharmaceuticals Beijing Co Ltd is 18.06 HKD with a low forecast of 14.67 HKD and a high forecast of 23.48 HKD.

Lowest Forecast
Wall Street Target
14.67 HKD
43% Upside
Average Forecast
Wall Street Target
18.06 HKD
76% Upside
Highest Forecast
Wall Street Target
23.48 HKD
129% Upside
Lowest
Price Target
14.67 HKD
43% Upside
Average
Price Target
18.06 HKD
76% Upside
Highest
Price Target
23.48 HKD
129% Upside
Biocytogen Pharmaceuticals Beijing Co Ltd Competitors:
Price Targets
RARE
Ultragenyx Pharmaceutical Inc
116% Upside
H
145020
Hugel Inc
12% Upside
SNSE
Sensei Biotherapeutics Inc
166% Upside
XBIT
XBiotech Inc
108% Upside
RARE
Ultragenyx Pharmaceutical Inc
116% Upside
H
145020
Hugel Inc
12% Upside
SNSE
Sensei Biotherapeutics Inc
166% Upside
XBIT
XBiotech Inc
108% Upside
B
300289
Beijing Leadman Biochemistry Co Ltd
259% Upside
ALPRE
Predilife SA
56% Upside
603387
Getein Biotech Inc
280% Upside
KNTE
Kinnate Biopharma Inc
9% Downside

Revenue
Forecast

Revenue Estimate
Biocytogen Pharmaceuticals Beijing Co Ltd

For the last 2 years the compound annual growth rate for Biocytogen Pharmaceuticals Beijing Co Ltd's revenue is 42%. The projected CAGR for the next 3 years is 25%.

42%
Past Growth
25%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Biocytogen Pharmaceuticals Beijing Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Biocytogen Pharmaceuticals Beijing Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's stock price target?
Price Target
18.06 HKD

According to Wall Street analysts, the average 1-year price target for Biocytogen Pharmaceuticals Beijing Co Ltd is 18.06 HKD with a low forecast of 14.67 HKD and a high forecast of 23.48 HKD.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Revenue forecast?
Projected CAGR
25%

For the last 2 years the compound annual growth rate for Biocytogen Pharmaceuticals Beijing Co Ltd's revenue is 42%. The projected CAGR for the next 3 years is 25%.

ALPHA SPREAD
Join more than 134,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.